NY-GOLDEN-FALCON
Golden Falcon Acquisition Corp. (the “Company ”) announced today that it priced its initial public offering of 30,000,000 units, upsized from 25,000,000 units, at $10.00 per unit. The units will be listed on the New York Stock Exchange (“NYSE ”) and will begin trading tomorrow, Friday, December 18, 2020 under the ticker symbol “GFX.U ”. Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on the NYSE under the symbols “GFX ” and “GFX WS ” respectively. The offering is expected to close on December 22, 2020.
The Company, led by Makram Azar and Scott Freidheim, was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. While the Company may pursue an initial business combination with any target business and in any sector or geographical location, it intends to focus its search on companies operating in the technology, media, telecommunications and fintech sectors that are headquartered in Europe, Israel, the Middle East or North America.
UBS Securities LLC and Moelis & Company LLC are acting as joint book-running managers of this offering and EarlyBirdCapital, Inc. as lead manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 4,500,000 units to cover over-allotments, if any. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from UBS Securities LLC, Attn: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone at (888) 827-7275, or by e-mail at olprospectusrequest@ubs.com .
A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC ”) and became effective on December 17, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Golden Falcon Acquisition Corp.
The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganisation or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on companies in the technology, media, telecommunications and fintech sectors that are headquartered in Europe, Israel, the Middle East or North America. The Company is led by Chief Executive Officer, Makram Azar, and Chairman, Scott Freidheim.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds thereof. No assurance can be given that the offering discussed above will be completed on the terms described, or at all , or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006206/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Second Front Systems Announces 10 Customers Prepared to Deploy on AWS European Sovereign Cloud via Game Warden® Platform3.12.2025 14:30:00 CET | Press release
Unlocks opportunity for Second Front customers to support European nations with strict data sovereignty requirements. Second Front Systems (2F), a Technology Partner in the Amazon Web Services (AWS) Partner Network (APN) and Global Security and Compliance Acceleration (GSCA) Program, today announced that ten of its existing customers have prepared for deployment onto AWS European Sovereign Cloud (ESC) via its 2F Game Warden® platform. This builds on Second Front's September announcement that 2F Game Warden will serve as an on-ramp to ESC. Independent software vendors (ISVs) seeking to support European organizations face complex regulatory requirements, including Germany's C5, and the EU's Digital Operational Resilience Act (DORA) and NIS2 Directive. By leveraging 2F Game Warden, ISVs can inherit a number of controls and expedite compliance with security frameworks. This collaboration unlocks a pre-validated solution for ISVs to meet these stringent compliance requirements while maintai
ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release
Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e
Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release
Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release
Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa
Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release
News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom